Abstract 398: Real-life example of biobanking: results of the PATH Biobank

@article{Anzeneder2016Abstract3R,
  title={Abstract 398: Real-life example of biobanking: results of the PATH Biobank},
  author={Tobias Anzeneder and U. Ohlms and Heinz Bodenm{\"u}ller},
  journal={Cancer Research},
  year={2016},
  volume={76},
  pages={398-398}
}
Introduction: Since 2002, PATH Foundation has kept a biobank collecting high-quality fresh frozen breast cancer specimens adhering to uniform SOPs at seven certified breast cancer centres in Germany. Research groups from academia and industry can obtain samples after application and review. PATH Biobank is a not-for-profit organisation and asks for a cost recovery fee in exchange for sample allocation to sustainably finance the expenses it incurs. Material and methods: The PATH Biobank consists… Expand
1 Citations
Differential regulation of AMP-activated protein kinase in healthy and cancer cells explains why V-ATPase inhibition selectively kills cancer cells
TLDR
The results of this work indicate that V-ATPase inhibition has differential effects on AMPK-mediated metabolic regulation in cancer and healthy cells and explain the tumor-specific cytotoxicity of V-atspase inhibition. Expand

References

SHOWING 1-5 OF 5 REFERENCES
Patients and Methods of the PATH Biobank - A Resource for Breast Cancer Research.
TLDR
Compared with data on therapy from WBC and the DMP breast cancer in Bavaria or, respectively, North Rhineland reports, the PATH patients represent an only slightly selected sample, which is a poorly used data and sample source. Expand
AGR3 in Breast Cancer: Prognostic Impact and Suitable Serum-Based Biomarker for Early Cancer Detection
TLDR
The data clearly show the potential usability of AGR3 and AGR2 as biomarkers for blood-based early detection of human breast cancer. Expand
The Treatment of Primary Breast Cancer in Older Women With Adjuvant Therapy: A Retrospective Analysis of Data From Over 3000 Patients From the PATH Biobank, With Two-Year Follow-up.
TLDR
The cause of these age-related differences in treatment is unclear, but it cannot be determined whether concomitant disease, the older patients' individual decisions, or other factors were responsible for their not receiving treatment as often as the younger patients did. Expand
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
TLDR
Broad treatment recommendations are presented, recognizing that detailed treatment decisions need to consider disease extent, host factors, patient preferences, and social and economic constraints. Expand
Reprogramming of the ERRα and ERα target gene landscape triggers tamoxifen resistance in breast cancer.
TLDR
The results suggest that ERα and ERRα cooperate to promote endocrine resistance, and they provide a rationale for the exploration of ERR α as a candidate drug target to treat endocrine-resistant breast cancer. Expand